arrow_back Trending Legislation
Share share

Tax Credits for Neurodegenerative and Psychiatric Research

This act introduces new tax credits for companies and organizations conducting research on neurodegenerative diseases and psychiatric conditions. The goal is to accelerate the development of new treatments and therapies, potentially improving access to care and quality of life for affected individuals.
Key points
Businesses and organizations can receive a 25% tax credit for expenses related to neurodegenerative and psychiatric research.
The government will allocate billions of dollars for these credits from 2024-2029, prioritizing projects with high scientific merit.
Tax credits can be transferred between non-profit entities and their project partners, facilitating collaboration.
The act aims to support the development of new therapeutics and devices, as well as the repurposing of existing drugs for new uses.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Mental Health Research Accelerator Act of 2023
Print number: HR 5821
Sponsor: Rep. Thompson, Mike [D-CA-4]
Process start date: 2023-09-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Tax Credits for Neurodegenerative and Psychiatric Research

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5821.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-28.

What are the main provisions?

Key points include:

  • Businesses and organizations can receive a 25% tax credit for expenses related to neurodegenerative and psychiatric research.
  • The government will allocate billions of dollars for these credits from 2024-2029, prioritizing projects with high scientific merit.
  • Tax credits can be transferred between non-profit entities and their project partners, facilitating collaboration.
  • The act aims to support the development of new therapeutics and devices, as well as the repurposing of existing drugs for new uses.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Thompson, Mike [D-CA-4].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Ways and Means.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 5821

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Taxes